RxDoctor Payments Data

Katharine Yang

Hospitalist · San Francisco, CANPI 1912401688

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,354 and has fallen 73.8% since, to $617 in 2025. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,836in general payments, 2019–2025

Across 123 payments — averaging $39.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$544
  • Boston Scientific$510
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$368
  • Novartis$339
  • Heartflow, Inc.$292
  • Regeneron Healthcare Solutions, Inc.$278
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$4,74498%
  • Education$912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,836 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$33,356
EntrestoSacubitril/Valsartan24$29,285
XareltoRivaroxaban20$28,670
Metoprolol Succinate47$469
Atorvastatin Calcium47$449
Bumetanide12$287
Carvedilol32$259
Spironolactone29$208
Furosemide32$135
Chlorthalidone14$121
Lisinopril28$111
Losartan Potassium16$90
Metoprolol Tartrate21$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$95$33,35633 claims
NovartisEntresto$339$29,28524 claims
Johnson & JohnsonXarelto$140$28,67020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.

Other hospitalist in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →